Observational studyMedicine2018

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study.

Junjie Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.